West Pharmaceutical Services, Inc. (NYSE:WST) Shares Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its position in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 11.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,772 shares of the medical instruments supplier’s stock after purchasing an additional 495 shares during the period. Oppenheimer & Co. Inc.’s holdings in West Pharmaceutical Services were worth $1,680,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in WST. Planned Solutions Inc. acquired a new position in West Pharmaceutical Services during the fourth quarter worth $39,000. Addison Advisors LLC increased its position in shares of West Pharmaceutical Services by 28.9% during the fourth quarter. Addison Advisors LLC now owns 183 shares of the medical instruments supplier’s stock worth $64,000 after acquiring an additional 41 shares during the period. Livforsakringsbolaget Skandia Omsesidigt increased its position in shares of West Pharmaceutical Services by 90.0% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 190 shares of the medical instruments supplier’s stock worth $67,000 after acquiring an additional 90 shares during the period. Lindbrook Capital LLC increased its position in shares of West Pharmaceutical Services by 46.0% during the fourth quarter. Lindbrook Capital LLC now owns 235 shares of the medical instruments supplier’s stock worth $83,000 after acquiring an additional 74 shares during the period. Finally, Tompkins Financial Corp purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $89,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the transaction, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. StockNews.com lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Friday, February 16th. KeyCorp upped their price objective on West Pharmaceutical Services from $440.00 to $470.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 13th. Finally, UBS Group cut their price objective on West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a research report on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, West Pharmaceutical Services has an average rating of “Moderate Buy” and an average target price of $435.20.

Check Out Our Latest Analysis on West Pharmaceutical Services

West Pharmaceutical Services Stock Performance

NYSE:WST opened at $314.68 on Monday. The firm has a market capitalization of $22.92 billion, a PE ratio of 41.51, a price-to-earnings-growth ratio of 5.56 and a beta of 1.01. The business’s fifty day moving average price is $359.68 and its 200 day moving average price is $362.62. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95. West Pharmaceutical Services, Inc. has a 12 month low of $310.42 and a 12 month high of $415.73.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last posted its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 EPS for the quarter, beating the consensus estimate of $1.29 by $0.27. The firm had revenue of $695.40 million for the quarter, compared to analyst estimates of $670.62 million. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. West Pharmaceutical Services’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.98 earnings per share. On average, sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 7.76 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 31st will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.25%. The ex-dividend date is Wednesday, July 31st. West Pharmaceutical Services’s payout ratio is 10.55%.

West Pharmaceutical Services Company Profile

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Stories

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.